Clene Inc. announced that it will provide an update on its CNM-Au8® program for amyotrophic lateral sclerosis (ALS) during a webcast scheduled for December 3, 2025, at 8:30 a.m. ET. The presentation will be led by company executives and a key opinion leader. The company has not yet presented the results of the program; the update is planned for the upcoming webcast. An archived version of the webcast will be available on Clene Inc.'s website following the event.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595763-en) on December 02, 2025, and is solely responsible for the information contained therein.
Comments